Normal-lung CT response was partly reproducible across RT courses, while short retreatment intervals increased response in previously irradiated lung.
Central thoracic re-irradiation achieved 80.1% one-year local control, while cumulative esophageal V60 emerged as a potential toxicity signal.
UTE-MRI-derived synthetic CT produced <1% target-dose differences and a 95.4% gamma pass rate at 2%/2 mm.
Grade 3 toxicity was 16.7% for ultracentral versus 8.7% for central lung tumors, with no grade ≥4 events in this real-world cohort.
In a prospective proton registry enriched for ultracentral, large, and re-irradiated lung tumors, two-year local control was 77% with no grade ≥3 toxicity.
In POLCAR, a four-point symptom threshold detected seven of eight pneumonitis cases and achieved a 97% negative predictive value.
Despite a mean whole-heart dose below 9 Gy, eleven cardiac substructures averaged above 10 Gy, and targeted replanning substantially reduced coronary exposure.
Radical radiotherapy use nearly doubled while five-year lung cancer-specific survival rose from 21.9% to 33.1% across Northern Ireland.
Cardiovascular events occurred in 59% after definitive lung chemoradiotherapy, while higher heart V20 and V30 independently tracked with greater event risk.
Unplanned radiotherapy interruptions occurred in 35% and were associated with lower response, more toxicity and markedly worse six-month survival.
Prospective REQUITE data showed substantial pulmonary toxicity after lung radiotherapy, with several sex-specific differences in symptoms and recovery.
Single-fraction SBRT achieved 100% estimated 12-month local control without grade ≥3 toxicity in a selected 49-patient cohort.
Whole-lung, physical-dose and BED3 models performed similarly externally, with the best complete-model AUC only 0.684 and inadequate calibration.
Life-threatening bilateral pneumonitis with concurrent Pneumocystis infection developed three days after carbon-ion RT in a patient previously treated with nivolumab.
Planning on selected respiratory phases reduced lung, heart and esophageal dose, but the optimal phase differed by toxicity endpoint.